Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies

References

• Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60(5):543–551.
   PubMed Web of Science ®Google Scholar
• Wettermark B. The intriguing future of pharmacoepidemiology. Eur J Clin Pharmacol. 2013;69(Suppl 1):43–51.
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al., et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
   PubMed Web of Science ®Google Scholar
• Bachhav SS, Kshirsagar NA. Systematic review of drug utilization studies & the use of the drug classification system in the WHO-SEARO region. Indian J Med Res. 2015;142(2):120–129.
   PubMed Web of Science ®Google Scholar
• Yoo KB, Lee SG, Park S, et al., et al. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea. BMJ Open. 2015;5(7):e006940.
   Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al., et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2010;1:141.
   PubMed Web of Science ®Google Scholar
• Latry P, Molimard M, Bégaud B, et al. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol. 2010;66(7):743–748.
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, et al. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacol Econ. 2009;27(5):435–438.
   PubMed Web of Science ®Google Scholar
• Hesse U, Godman B, Petzold M, et al. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy. 2013;11(6):677–685.
   PubMedGoogle Scholar
• Vončina L, Strizrep T, Godman B, et al., et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469–479.
   PubMed Web of Science ®Google Scholar
• Sakshaug S, Furu K, Karlstad Ø, et al. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476–481.
   PubMed Web of Science ®Google Scholar
• Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761–766.
   PubMed Web of Science ®Google Scholar
• Bucsics A, Godman B, Burkhardt T, et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):809–819.
   PubMed Web of Science ®Google Scholar
• Markovic-Pekovic V, Škrbić R, Godman B, et al. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):661–671.
   PubMed Web of Science ®Google Scholar
• Tamosiunas A, Luksiene D, Baceviciene M, et al., et al. Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania. Plos One. 2014;9(12):e114283.
   PubMed Web of Science ®Google Scholar
• Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Therapy/Sponsored by Int Soc Cardiovasc Pharmacother. 2014;28(1):99–109.
   PubMed Web of Science ®Google Scholar
• Wladysiuk M, Araszkiewicz A, Godman B, et al. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy. 2011;9(2):101–110.
   PubMedGoogle Scholar
• Hynd A, Roughead EE, Preen DB, et al. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf. 2008;17(11):1091–1099.
   PubMed Web of Science ®Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, et al. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur J Clin Pharmacol. 2004;60(7):503–511.
   PubMed Web of Science ®Google Scholar
• Bajcetic M, Kalaba M, Godman B, et al., et al. Ongoing programmes to reduce the high rate of antibiotic consumption in Serbia; current situation and future direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 3):98.
   Google Scholar
• Moon J, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications. Front Pharmacol. 2014;5(Article 219):1–10.
   PubMed Web of Science ®Google Scholar
• Godman B, Persson M, Miranda J, et al., et al. Changes in the utilization of venlafaxine after the introduction of generics in Sweden. Appl Health Econ Health Policy. 2013;11(4):383–393.
   PubMedGoogle Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469–482.
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovič J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–349.
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Alonderis T, Marcinkevičius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. EuroHealth. 2011;17:1–4.
   Google Scholar
• Godman B, Acurcio F, Guerra Júnior AA, et al., et al. Initiatives among authorities to improve the quality and efficiency of prescribing and the implications. Jn Pharma Care Health Sys. 2014;1(3):15.
   Google Scholar
• Kadusevicius E, Jankauskiene D, Paulauskaite I, et al. Policy implications of rationalization of statin use in Lithuania. Int J Technol Assess Health Care. 2009;25(3):419–424.
   PubMed Web of Science ®Google Scholar
• Godman B, Malmstrom R, Bennie M, et al., et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?’. Rev Health Care. 2012;3(1):5–16.
   Google Scholar
• Kadusevicius E, Mikucionyte L, Maciulaitis R, et al. Trends in the consumption of antidepressant drugs in Lithuania in 2002–2004. Medicina (Kaunas, Lithuania). 2006;42(12):1020–1029.
   PubMedGoogle Scholar